Article
Endocrinology & Metabolism
Amy A. Swanson, Dana Erickson, Diane Mary Donegan, Sarah M. Jenkins, Jamie J. Van Gompel, John L. D. Atkinson, Bradley J. Erickson, Caterina Giannini
Summary: This study analyzed histologic subtypes of growth hormone-producing pituitary adenomas in acromegaly patients and found that histologic subtype did not predict surgical outcome, while absence of invasion and lower pre-operative IGF-1 index were significantly associated with post-surgical remission.
Article
Oncology
Chen-Xi Liu, Li-Jun Heng, Yu Han, Sheng-Zhong Wang, Lin-Feng Yan, Ying Yu, Jia-Liang Ren, Wen Wang, Yu-Chuan Hu, Guang-Bin Cui
Summary: Texture signatures based on multiparametric MRI images may serve as useful biomarkers for differentiating subtypes of GH-secreting PA patients.
FRONTIERS IN ONCOLOGY
(2021)
Review
Endocrinology & Metabolism
Antonio Bianchi, Sabrina Chiloiro, Antonella Giampietro, Simona Gaudino, Rosalinda Calandrelli, Ciro Mazzarella, Carmelo Caldarella, Mario Rigante, Marco Gessi, Liverana Lauretti, Laura De Marinis, Alessandro Olivi, Alfredo Pontecorvi, Francesco Doglietto
Summary: Growth hormone-secreting adenomas exhibit a wide range of behaviors and outcomes, from mild disease to aggressive neoplasms. Treatment for patients who do not respond to surgery or first-generation somatostatin receptor ligands may involve multiple surgical, medical, and radiation treatments. Currently, there are no markers that can predict the prognosis or aggressiveness of acromegaly. A multidisciplinary approach is necessary to tailor treatment for difficult/aggressive cases, including radiation therapy, chemotherapy, and emerging treatments.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Jiun-Lin Yan, Mao-Yu Chen, Yao-Liang Chen, Chi-Cheng Chuang, Peng-Wei Hsu, Kuo-Chen Wei, Chen-Nen Chang
Summary: This study evaluated the outcomes of the endoscopic transsphenoidal approach as the primary treatment for somatotroph adenomas and investigated patients with suboptimal surgical results. Factors such as tumor size, preoperative GH level, and residual tumors were found to be associated with surgical failure. Octreotide showed good outcomes for treating DGSA patients, while SRS/EXRT generated good results for patients receiving secondary treatments when remission could not be reached after 6 months of TSA operation.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Chenxing Ji, Wen Xu, Hong Ding, Zhengyuan Chen, Chengzhang Shi, Jie Han, Liang Yu, Nidan Qiao, Yichao Zhang, Xiaoyun Cao, Xiang Zhou, Haixia Cheng, Huijin Feng, Cheng Luo, Zhiyu Li, Bing Zhou, Zhao Ye, Yao Zhao
Summary: Our study found that the expression of p300 is elevated in GHPA tissues compared to normal pituitary tissues. Knockdown of p300 inhibits cell proliferation and clone formation. Treatment with A-485 can suppress cell growth and inhibit GH secretion both in vitro and in vivo. Mechanistic studies showed that A-485 can downregulate the expression or activity of several oncogenes involved in the Pttg1, c-Myc, cAMP, and PI3K/AKT/mTOR signaling pathways, which play crucial roles in PA tumorigenesis and progression.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Beata Rak, Maria Maksymowicz, Monika Pekul, Grzegorz Zielinski
Summary: The study found that densely granulated corticotroph adenomas occurred at a younger age, were more commonly microadenomas compared to sparsely granulated tumors, less frequently had invasive features, and more commonly achieved immediate postsurgical hormonal remission. This highlights the importance of accurately differentiating between densely granulated and sparsely granulated subtypes in the pathomorphological diagnosis of corticotropic tumors, especially in invasive PitNETs.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Junpei Sanada, Fuminori Tatsumi, Shinji Kamei, Yoshiro Fushimi, Masashi Shimoda, Kenji Kohara, Shuhei Nakanishi, Kohei Kaku, Tomoatsu Mune, Hideaki Kaneto
Summary: Pituitary adenoma producing both growth hormone (GH) and thyroid-stimulating hormone (TSH) is rare but possible. This case study presented a 27-year-old woman with symptoms of acromegaly and simultaneous production of both GH and TSH by the pituitary adenoma. Treatment included pituitary tumor resection, cyber knife therapy, somatostatin analog, GH receptor antagonist, and anti-thyroid drug thiamazole.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Clinical Neurology
Charles Ashton, Suhn K. Rhie, John D. Carmichael, Gabriel Zada
Summary: Profiling of human pituitary adenoma DNA methylome identified KCNAB2 as differentially methylated between NFPAs and GH-secreting PAs. Modulation of Kcnab2 expression in GH3 cells affected GH secretion, and quinidine administration reduced GH secretion in a dose-dependent manner. These findings suggest potential new therapeutic targets for acromegaly.
JOURNAL OF NEUROSURGERY
(2021)
Review
Endocrinology & Metabolism
Li Li, Liheng Meng, Yuping Liu, Rashi Tamrakar, Xi Yang, Xinghuang Liang, Jia Zhou, Jing Xian, Zhenxing Huang, Yingfen Qin
Summary: Mixed pituitary TSH/GH adenomas are rare adenomas that produce both GH and TSH simultaneously, often associated with acromegaly and thyrotoxicosis. Treatment typically involves somatostatin analogs to regulate hormone levels before surgery.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Charlotte Aagaard, Amanda S. Christophersen, Susanne Finnerup, Christian Rosendal, Helga A. Gulisano, Kare S. Ettrup, Peter Vestergaard, Jesper Karmisholt, Eigil Husted Nielsen, Jakob Dal
Summary: This study investigated the prevalence and patient characteristics of acromegaly over time, as well as the impact of treatment changes on disease control. The study found that the prevalence of acromegaly has increased significantly, with a shift towards a milder clinical phenotype. Modern treatment approaches enable individualized treatment and disease control in the majority of patients with acromegaly.
CLINICAL ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Stefano Frara, Meliha Melin Uygur, Luigi di Filippo, Mauro Doga, Marco Losa, Simona Santoro, Pietro Mortini, Andrea Giustina
Summary: This study aimed to evaluate the prevalence and determinants of morphometric vertebral fractures (VFs) in patients with recently diagnosed acromegaly. The results showed a higher prevalence of VFs in acromegaly patients compared to controls, and it was found to be associated with GH levels. Therefore, VF assessment should be included in the diagnosis of acromegaly.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Caiyan Mo, Han Chen, Fang Wang, Ying Guo, Yao Wang, Tao Tong, Liyong Zhong
Summary: This study found that UA levels are associated with disease activity in patients with GHPA. UA gradually decreased as IGF-1 levels decreased. At 12 months postoperatively, UA levels were significantly lower in the biochemical remission group than in the nonremission group.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Clinical Neurology
Yasuyuki Kinoshita, Akira Taguchi, Atsushi Tominaga, Kazunori Arita, Fumiyuki Yamasaki
Summary: Recovery from AGHD after initial TSS is more likely in younger female patients with higher peak GH levels assessed by preoperative PPT. Patients aged <= 62.2 years and with a peak GH level of >= 0.74 μg/L based on preoperative PPT are likely to recover from AGHD.
JOURNAL OF NEUROSURGERY
(2021)
Article
Endocrinology & Metabolism
Ning Ai Liu, Anat Ben-Shlomo, John D. Carmichael, Christina Wang, Ronald S. Swerdloff, Anthony P. Heaney, Garni Barkhoudarian, Daniel Kelly, Mazen Noureddin, Lin Lu, Manish Desai, Yana Stolyarov, Kevin Yuen, Adam N. Mamelak, James Mirocha, Mourad Tighiouart, Shlomo Melmed
Summary: Seliciclib may directly target pituitary corticotrophs in patients with Cushing's disease and reverse hypercortisolism. However, further research is needed regarding the liver toxicity associated with seliciclib.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
In-Ho Jung, Seonah Choi, Cheol Ryong Ku, Sang-Guk Lee, Eun Jig Lee, Sun Ho Kim, Eui Hyun Kim
Summary: This study evaluated the reliability of IGF-1 levels as an alternative for disease monitoring after surgical treatment of acromegaly. The results showed that IGF-1 levels can serve as a reliable alternative to OGTT and play a valuable role in monitoring acromegaly status.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)